回调或由获利了结导致 10月8日，港股早盘低开。Wind数据显示，截至收盘，恒生指数下跌0.48%，报26829.46点。同期，恒 生科技指数下跌0.55%，报6514.19点。 10月8日，国庆假期最后一天，港股遭遇回调。具体来看，截至收盘，恒生指数、恒生科技指数双双下 跌0.48%、0.55%。若拉长时间至10月以来，港股市场则呈现先扬后抑态势，恒生指数突破年内新高后 连续回调。回顾年内，在港股走势表现亮眼的背景下，多只港股主题基金业绩突出，最高已赚155%。 有业内人士指出，未来港股仍有向上空间，科技板块仍将是市场关注的焦点，板块或呈现"波动上行、 龙头领跑"的格局。港股主题基金未来仍具备较好的投资机会，特别是聚焦新经济、科技和创新产业的 基金。 值得关注的是，在港股细分板块中，创新药行情的"狂飙"备受关注。仅从市场多只指数基金跟踪的中证 港股通创新药指数来看，据中证指数官网，截至9月30日，该指数年内涨幅已达118.52%。 这一背景下，多家公募旗下的港股创新药ETF或相关被动指数基金的前三季度收益也均翻倍，包括万家 中证港股通创新药ETF、景顺长城中证港股通创新药ETF、中欧中证港股通创新药指数A/ ...

回调或由获利了结导致 10月8日，国庆假期最后一天，港股遭遇回调。具体来看，截至收盘，恒生指数、恒生科技指数双双下跌0.48%、0.55%。若 拉长时间至10月以来，港股市场则呈现先扬后抑态势，恒生指数突破年内新高后连续回调。回顾年内，在港股走势表现亮 眼的背景下，多只港股主题基金业绩突出，最高已赚155%。有业内人士指出，未来港股仍有向上空间，科技板块仍将是市 场关注的焦点，板块或呈现"波动上行、龙头领跑"的格局。港股主题基金未来仍具备较好的投资机会，特别是聚焦新经济、 科技和创新产业的基金。 就具体产品看，截至9月末，汇添富香港优势精选混合C类份额和A类份额的前三季度收益率分别达155.14%和155.09%，排 名全市场基金收益第三、四名。同期，中银港股通医药混合发起A/C的收益率也达126.55%、125.48%，排名居前。 值得关注的是，在港股细分板块中，创新药行情的"狂飙"备受关注。仅从市场多只指数基金跟踪的中证港股通创新药指数来 看，据中证指数官网，截至9月30日，该指数年内涨幅已达118.52%。 这一背景下，多家公募旗下的港股创新药ETF或相关被动指数基金的前三季度收益也均翻倍，包括万家中证 ...

（原标题：39只"翻倍基"，最新业绩来了） 【导读】前三季度主动权益基金平均业绩超29%，39只"翻倍基"，最牛接近195% 中国基金报记者 方丽 孙晓辉 今年前三季度，A股市场持续走强，结构性亮点纷呈，科技成长与资源品板块领涨，公募权益基金赚钱效应显著，业绩翻倍基金批量诞生！ 具体来看，主流指数前三季度总体上演上涨行情，其中科创创业50年内涨幅达到63.04%，表现最好；创业板指、科创50、北证50、中证2000等指 数表现强势，涨幅超30%，仅红利指数、中证红利出现下跌。 从申万一级行业来看，前三季度行业表现也出现巨大分化。有色金属、通信、电子位居前三，年内涨幅均超50%，电力设备、综合、机械设备、 传媒、汽车、计算机、基础化工、医药生物等板块涨幅超过20%；煤炭、食品饮料、石油石化、交通运输等板块逆势下跌。 在这样的基础市场下，前三季度主动权益基金单位净值增长率平均达到29.24%，最牛基金涨幅接近195%。 主动权益基金前三季度单位净值 平均涨29.24% 受益于股市上涨，今年前三季度权益类基金交出了亮眼的成绩单。 Wind数据显示，若不计算2025年成立的新基金，前三季度权益基金平均获得30.04% ...

本文共1900 字 阅读完约7分钟 金融投资报记者 刘庆华 三季度行情即将收官。在经历了一季度的震荡上行，一季度末和二季度初的调整之后，A股市场和港股 市场自4月中旬以来持续走高，并在三季度迭创阶段新高，投向股票资产的基金也获得了不错的收益。 Wind数据显示，今年以来截至9月26日，在权益类基金和QDII基金中，合计共有37只基金收益率翻倍。 主动管理的A股权益类基金中，重仓AI的基金收益率领先，单只基金收益率最高接近190%。被动指数 型基金中，跟踪创新药、通信、人工智能等方向的基金收益率居前。 01 主动权益基金：31只基金收益翻倍 投向A股的主动权益类基金今年以来表现不俗，超额回报出色。截至9月26日，算术平均收益率为 30.32%（剔除年内成立的基金），超过98%的主动权益类基金取得正收益，收益率超50%的基金达到 684只，占比超15%。其中，收益率超过100%的基金有31只，单只基金最高收益率接近190%。 永赢科技智选A以189.58%的收益率领跑。二季度以来该基金净值涨幅明显，近半年的收益率超过了 164%。从基金季报可以看到，二季度末该基金有明显的调仓动作，前十大重仓股全部更换，将持仓重 ...

万家中证港股通创新药ETF成立于2024年9月13日，截至2025年9月25日，其今年来收益率为109.14%， 成立来收益率为85.99%，累计净值为1.8599元。 | 基金名称 | 万家中证港股通创新药交易型开放式指数证 | | --- | --- | | | 券投资基金 | | 基金简称 | 万家中证港股通创新药 ETF | | 基金主代码 | 520700 | | 基金管理人名称 | 万家基金管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办 | | | 法》 | | 基金经理变更类型 | 解聘基金经理 | | 共同管理本基金的基金经理姓名 | 贺方舟 | | 离任基金经理姓名 | 杨坤 | 中国经济网北京9月26日讯今日，万家基金公告，杨坤离任万家中证港股通创新药ETF。 杨坤曾任Fractabole量化IT工程师等职，2015年6月入职万家基金管理有限公司，历任量化投资部研究 员，现任基金经理。 ...

Core Viewpoint - The article discusses the recent trend of residents shifting their savings from bank deposits to the stock market and mutual funds, driven by a recovering market and declining deposit interest rates. The public fund industry has seen significant growth, with the total net asset value reaching 35.08 trillion yuan, an increase of 2.25 trillion yuan from the previous year [6][9][20]. Group 1: Market Performance - The Shanghai Composite Index has surpassed 3,800 points, marking a ten-year high, while the Hang Seng Index has crossed 26,000 points with a year-to-date increase of nearly 33% [6][9]. - As of September 15, 2023, the public fund scale was 33.92 trillion yuan, a decrease of 1.16 trillion yuan from the end of July [19]. - In 2023, 98% of mutual funds have reported profits, with 2,582 funds yielding over 30% returns, and 39 funds exceeding 100% returns [9][10]. Group 2: Fund Manager Performance - Star fund managers like Zhang Kun and Ge Lan have seen significant changes in their fund management scales, with Zhang's scale dropping from 1,019.35 billion yuan to 550.47 billion yuan [16]. - Ge Lan's fund, which focused on the pharmaceutical sector, experienced a cumulative decline of over 65% from July 2021 to September 2024, but has recently rebounded by 52.37% in the past year [14][16]. - The article highlights a shift in investor sentiment, with many choosing to exit funds once they break even, reflecting a "holding paradox" in the mutual fund industry [19]. Group 3: Investment Trends - The article notes that the current market is characterized by a "slow bull" phase, with many investors returning to their accounts to find that their funds have recovered or gained value [8][10]. - The trend of residents moving their savings into the stock market and mutual funds is expected to continue, especially as deposit rates decline and the capital market strengthens [20][22]. - Analysts predict that the issuance of new funds will increase in the second half of the year, enhancing market activity [21].

Core Viewpoint - The A-share market has shown significant strength in the first eight months of the year, leading to a strong performance of public equity funds, with many funds achieving over 100% returns [2][6][13]. Group 1: Market Performance - The main indices have experienced substantial gains, with the North Exchange 50 index rising by 51.49%, and several other indices, including the Sci-Tech Innovation 50 and the ChiNext index, increasing by over 30% [2][4]. - In August, the Shanghai Composite Index broke through the 3,800-point mark, reaching a 10-year high, with the Sci-Tech series indices showing strong performance, with increases of 32.25% and 28.00% respectively [4]. Group 2: Fund Performance - The average net value growth rate of active equity funds in the first eight months reached 23.83%, with the best-performing fund achieving a growth rate exceeding 175% [6][10][11]. - A total of 603 active equity funds have recorded a net value growth rate exceeding 50%, with 21 funds surpassing 100% [13][20]. - The average net value growth rates for ordinary stock funds and mixed equity funds were 28.38% and 28.79% respectively, indicating strong recovery in net values [9]. Group 3: Sector Opportunities - Structural opportunities have emerged in sectors such as the North Exchange, innovative pharmaceuticals, humanoid robots, AI, and semiconductors, contributing to the strong performance of funds managed by adept fund managers [12][20]. - The innovative pharmaceutical sector has been a standout performer, with the Hong Kong Stock Connect innovative pharmaceutical index showing a cumulative annual increase of 108.24% [24]. Group 4: Future Outlook - If the current market trends continue, 2025 is expected to be a breakout year for active equity fund performance [21]. - The market is experiencing a rebalancing of underlying funds, with indications of capital flowing from dollar assets to non-dollar assets, and from the bond market to the equity market [26].

Group 1 - The article provides a ranking of the top 10 open-end funds based on net asset value growth as of August 21, 2025, highlighting the performance of various funds [2][4][7] - The top-performing fund is "汇添富双鑫添利债券D" with a net value of 1.2019, showing a significant increase from 1.0000 [2] - The bottom-performing fund is "前海开源周期精选混合C," which has a net value of 1.0343, down from 1.0816 [4][7] Group 2 - The article notes that a total of 28,402 funds have updated their net values, indicating a broad market activity [3] - The sectors leading the market include multi-financial and telecommunications, both showing gains of over 2% [7] - The article mentions that the "万家中证港股通创新药ETF" has experienced rapid net value growth, indicating strong performance in the healthcare sector [7] Group 3 - The article discusses the concentration of holdings in the top funds, with "万家中证港股通创新药ETF" having a concentration of 67.67% in its top ten holdings, primarily in the pharmaceutical sector [8] - The top holdings in this fund include "信达生物" and "药明生物," which have shown significant daily increases [8] - Conversely, the "前海开源周期精选混合C" fund has a lower concentration of 58.34% in its top holdings, with notable declines in some of its key stocks [8]

Group 1 - The core point of the news is the appointment of He Fangzhou as a new fund manager for the Wanjiac Fund Management Co., Ltd.'s Hong Kong Stock Connect Innovative Drug ETF (520700) [1] - He Fangzhou has a background in fund operations and research, having previously worked at Huatai-PineBridge Fund Management Co., Ltd. and Da Cheng Fund Management Co., Ltd. [1] - The Wanjiac Hong Kong Stock Connect Innovative Drug ETF was established on September 13, 2024, and has shown a year-to-date return of 61.08% and a cumulative return of 43.25% since its inception, with a net asset value of 1.4325 yuan as of June 24, 2025 [1] Group 2 - The fund is officially named Wanjiac Hong Kong Stock Connect Innovative Drug Exchange-Traded Fund, with the main code 520700 [3] - The announcement is made in accordance with the "Publicly Raised Securities Investment Fund Information Disclosure Management Measures" [3] - The fund is co-managed by He Fangzhou and Yang Kun [3]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth, highlighting the top 10 funds with significant increases [2][4][5] - The top-performing funds include Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Fund A and C, with net values of 1.2442 and 1.2438 respectively, both showing a growth of 0.05 [2][4] - The article mentions that a total of 28,277 funds have updated their net values, indicating a broad market activity [3] Group 2 - The bottom 10 funds in terms of net value growth include Huafu Health and Entertainment Flexible Allocation Mixed Fund A and C, with significant declines [5] - The article notes that the Shanghai Composite Index experienced a rebound, while the ChiNext Index showed a mixed performance, with a trading volume of 1.61 trillion [7] - The leading sectors include communication equipment, which saw a rise of over 2%, while the aviation and software service sectors lagged [7] Group 3 - The article highlights that the top holdings in the funds are primarily in the pharmaceutical sector, with a concentration of 67.67% in the top 10 holdings of the funds [9] - Notable stocks among the top holdings include Innovent Biologics and WuXi Biologics, which experienced significant daily increases [9] - The funds are categorized into passive index funds tracking the Hong Kong Stock Connect Innovation Drug Index and active mixed funds focusing on the pharmaceutical sector [9]